TriSalus Life Sciences, Inc. (NASDAQ:TLSI) Given Average Rating of "Buy" by Brokerages

TriSalus Life Sciences, Inc. (NASDAQ:TLSI - Get Free Report) has received a consensus recommendation of "Buy" from the nine research firms that are covering the firm, MarketBeat reports. Seven analysts have rated the stock with a buy rating and two have given a strong buy rating to the company. The average twelve-month target price among brokerages that have covered the stock in the last year is $10.93.

Several research analysts have weighed in on the stock. Lake Street Capital assumed coverage on shares of TriSalus Life Sciences in a research note on Thursday, February 13th. They issued a "buy" rating and a $10.00 price objective on the stock. Canaccord Genuity Group reiterated a "buy" rating and issued a $11.00 price objective on shares of TriSalus Life Sciences in a research note on Friday, March 28th. Finally, Roth Mkm reiterated a "buy" rating and issued a $11.00 price objective on shares of TriSalus Life Sciences in a research note on Friday, January 24th.

Institutional Inflows and Outflows

Several hedge funds have recently modified their holdings of the business. Charles Schwab Investment Management Inc. acquired a new position in shares of TriSalus Life Sciences during the 1st quarter worth $55,000. Connective Capital Management LLC acquired a new position in shares of TriSalus Life Sciences during the 4th quarter worth $140,000. Bridgeway Capital Management LLC increased its stake in shares of TriSalus Life Sciences by 333.3% during the 4th quarter. Bridgeway Capital Management LLC now owns 65,000 shares of the company's stock worth $326,000 after purchasing an additional 50,000 shares during the last quarter. Bank of America Corp DE increased its stake in shares of TriSalus Life Sciences by 120,471.6% during the 4th quarter. Bank of America Corp DE now owns 178,446 shares of the company's stock worth $894,000 after purchasing an additional 178,298 shares during the last quarter. Finally, Northern Trust Corp increased its stake in shares of TriSalus Life Sciences by 22.7% during the 4th quarter. Northern Trust Corp now owns 32,112 shares of the company's stock worth $161,000 after purchasing an additional 5,936 shares during the last quarter. Institutional investors and hedge funds own 2.58% of the company's stock.

TriSalus Life Sciences Stock Performance

Shares of NASDAQ:TLSI opened at $5.07 on Wednesday. The company has a market cap of $163.62 million, a PE ratio of -2.04 and a beta of 0.50. TriSalus Life Sciences has a 52 week low of $3.50 and a 52 week high of $10.24. The firm has a 50 day simple moving average of $5.40 and a 200 day simple moving average of $4.98.

TriSalus Life Sciences (NASDAQ:TLSI - Get Free Report) last issued its quarterly earnings results on Thursday, March 27th. The company reported ($0.35) EPS for the quarter, meeting the consensus estimate of ($0.35). The firm had revenue of $8.26 million during the quarter, compared to analysts' expectations of $8.12 million. On average, equities analysts predict that TriSalus Life Sciences will post -1.55 earnings per share for the current year.

About TriSalus Life Sciences

TriSalus Life Sciences, Inc, a medical technology company, researches, develops, and sells drug delivery technologies and immune-oncology therapeutics for the treatment of liver and pancreatic cancer. The company offers Pressure Enabled Drug Delivery infusion systems, such as the TriNav infusion system, which is used in transarterial radioembolization and chemoembolization procedures for patients with liver cancer and metastases; and the Pancreatic Retrograde Venous Infusion device, which is in Phase 1 clinical trial, for locally advanced pancreatic cancer.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.